Lupin acquires nine brands of Medical Nutritional Institute in South Africa

MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome

Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun

Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

Lupin signs distribution agreement with Celnova for orphan drug NaMuscla

Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia

Vaishali Pharma plans M&A route to drive growth

Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies

Lupin inks licensing agreement with Takeda to commercialize Vonoprazan

Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India

Piramal Pharma's GHG Commitment Validated and Approved by SBTi

This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration

Lupin launches Mirabegron ER tablets in US

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development

Lupin launches Doxorubicin Hydrochloride Liposome Injection in US

ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA